CoChat

Therapeutic approaches for combating Pseudomonas aeruginosa infections

Jangra, Vijeta, Sharma, Namita, Chhillar, Anil Kumar · 2022 · Microbes and Infection
Cited by 66

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen responsible for acute hospital-acquired infections. This review described various therapeutic approaches to treat infections caused by P. aeruginosa, including conventional therapy, novel antibiotic treatments and treatments other than antibiotics. Most of the developments are still in research that will provide novel treatment options in future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.micinf.2022.104950

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 65

  1. Burrows, 2018, The therapeutic pipeline for Pseudomonas aeruginosa infections, ACS Infect Dis, 4, 1041, 10.1021/acsinfecdis.8b00112 · DOI · Paper page
  2. Sadikot, 2005, Pathogen–host interactions in Pseudomonas aeruginosa pneumonia, Am J Respir Crit Care Med, 171, 1209, 10.1164/rccm.200408-1044SO · DOI · Paper page
  3. Moore, 2011, Treatment strategies and recommendations for Pseudomonas aeruginosa infections, Clin Lab Sci, 24, 52, 10.29074/ascls.24.1.52 · doi:10.29074/ascls.24.1.52
  4. Lister, 2009, Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms, Clin Microbiol Rev, 22, 582, 10.1128/CMR.00040-09 · DOI · Paper page
  5. Breidenstein, 2011, Pseudomonas aeruginosa: all roads lead to resistance, Trends Microbiol, 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
  6. Zavascki, 2010, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy, Expert Rev Anti Infect Ther, 8, 71, 10.1586/eri.09.108 · DOI · Paper page
  7. Taylor, 2014, Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies, J Biotechnol, 191, 121, 10.1016/j.jbiotec.2014.09.003 · DOI · Paper page
  8. Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol Adv, 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  9. Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Genes Dis, 6, 109, 10.1016/j.gendis.2019.04.001 · DOI · Paper page
  10. Lima, 2020, β-Lactam antibiotics: an overview from a medicinal chemistry perspective, Eur J Med Chem, 208, 1, 10.1016/j.ejmech.2020.112829 · DOI · Paper page
  11. Becker, 2013, Aminoglycoside antibiotics in the 21st century, ACS Chem Biol, 8, 105, 10.1021/cb3005116 · DOI · Paper page
  12. Pham, 2019, Quinolone antibiotics, Med Chem Commun, 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
  13. Arnold, 2007, Polymyxin antibiotics for gram-negative infections, Am J Health Syst Pharm, 64, 819, 10.2146/ajhp060473 · DOI
  14. Sharma, 2021, Antibiotic adjuvants: a promising approach to combat multidrug-resistant bacteria, Curr Drug Targets, 22, 1334, 10.2174/1389450122666210120084406 · DOI
  15. Amaral, 2014, Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them, Front Pharmacol, 4, 1, 10.3389/fphar.2013.00168 · DOI · Paper page
  16. Venter, 2015, RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition, Front Microbiol, 6, 1, 10.3389/fmicb.2015.00377 · DOI · Paper page
  17. Auda, 2020, Efflux pumps of Gram-negative bacteria in brief, Gene Rep, 20, 1
  18. McCarthy, 2015, Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy, Semin Respir Crit Care Med, 36, 44, 10.1055/s-0034-1396907 · DOI
  19. Morita, 2012, MexXY multidrug efflux system of Pseudomonas aeruginosa, Front Microbiol, 3, 1, 10.3389/fmicb.2012.00408 · DOI · Paper page
  20. Wolter, 2013, Mechanisms of β-lactam resistance among Pseudomonas aeruginosa, Curr Pharmaceut Des, 19, 209, 10.2174/138161213804070311 · DOI · Paper page
  21. Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Genes Dis, 6, 109, 10.1016/j.gendis.2019.04.001 · DOI · Paper page
  22. Furtado, 2007, Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa, Int J Antimicrob Agents, 30, 315, 10.1016/j.ijantimicag.2007.05.017 · DOI
  23. Bassetti, 2018, How to manage Pseudomonas aeruginosa infections, Drugs Context, 7, 1, 10.7573/dic.212527 · DOI · Paper page
  24. Ramirez, 2010, Aminoglycoside modifying enzymes, Drug Resist Updates, 13, 151, 10.1016/j.drup.2010.08.003 · DOI · Paper page
  25. Chevalier, 2017, Structure, function and regulation of Pseudomonas aeruginosa porins, FEMS Microbiol Rev, 41, 1, 10.1093/femsre/fux020 · DOI · Paper page
  26. Purssell, 2013, Functional characterization of the NfxB repressor of the mexCD–oprJ multidrug efflux operon of Pseudomonas aeruginosa, Microbiol, 159, 1, 10.1099/mic.0.069286-0 · DOI · Paper page
  27. Kamali, 2020, Evaluation of antimicrobial resistance, biofilm-forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa, BMC Res Notes, 13, 1, 10.1186/s13104-020-4890-z · DOI · Paper page
  28. Rasamiravaka, 2015, The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms, BioMed Res Int, 1, 10.1155/2015/759348 · DOI · Paper page
  29. Grassi, 2017, Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents, Front Microbiol, 8, 1, 10.3389/fmicb.2017.01917 · DOI · Paper page
  30. Chatterjee, 2016, Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options, Int J Med Microbiol, 306, 48, 10.1016/j.ijmm.2015.11.004 · DOI · Paper page
  31. Chahine, 2010, Doripenem: a new carbapenem antibiotic, Am J Health Syst Pharm, 67, 2015, 10.2146/ajhp090672 · doi:10.2146/ajhp090672
  32. Queenan, 2010, Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem, Antimicrob Agents Chemother, 54, 565, 10.1128/AAC.01004-09 · DOI · Paper page
  33. Bazan, 2011, Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime, Med Clin North Am, 95, 743, 10.1016/j.mcna.2011.03.009 · doi:10.1016/j.mcna.2011.03.009
  34. Cox, 2018, Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes, ACS Infect Dis, 4, 980, 10.1021/acsinfecdis.8b00001 · DOI
  35. Eljaaly, 2019, Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections, Drugs, 79, 243, 10.1007/s40265-019-1054-3 · DOI · Paper page
  36. Cigana, 2016, Efficacy of the novel antibiotic POL7001 in preclinical models of Pseudomonas aeruginosa pneumonia, Antimicrob Agents Chemother, 60, 4991, 10.1128/AAC.00390-16 · DOI
  37. Werneburg, 2012, Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics, Chembiochem, 13, 1767, 10.1002/cbic.201200276 · DOI · Paper page
  38. Freinkman, 2012, Regulated assembly of the transenvelope protein complex required for lipopolysaccharide export, Biochemistry, 51, 4800, 10.1021/bi300592c · DOI · Paper page
  39. Srinivas, 2010, Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa, Science, 327, 1010, 10.1126/science.1182749 · DOI · Paper page
  40. Zhanel, 2014, Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli, Drugs, 74, 31, 10.1007/s40265-013-0168-2 · DOI · Paper page
  41. Garazzino, 2020, Ceftolozane/tazobactam for treating children with exacerbations of cystic fibrosis due to Pseudomonas aeruginosa: a review of available data, Front Pediatr, 8, 1, 10.3389/fped.2020.00173 · doi:10.3389/fped.2020.00173
  42. Shirley, 2018, Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections, Drugs, 78, 675, 10.1007/s40265-018-0902-x · DOI · Paper page
  43. Zhanel, 2013, Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination, Drugs, 72, 159, 10.1007/s40265-013-0013-7 · DOI · Paper page
  44. Wright, 2017, New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?, Clin Microbiol Infect, 23, 704, 10.1016/j.cmi.2017.09.001 · DOI · Paper page
  45. El Solh, 2009, Update on the treatment of Pseudomonas aeruginosa pneumonia, J Antimicrob Chemother, 64, 229, 10.1093/jac/dkp201 · DOI · Paper page
  46. Wagner, 2016, Novel strategies for the treatment of Pseudomonas aeruginosa infections, J Med Chem, 59, 5929, 10.1021/acs.jmedchem.5b01698 · DOI · Paper page
  47. Fothergill, 2012, Novel therapeutic strategies to counter Pseudomonas aeruginosa infections, Expert Rev Anti Infect Ther, 10, 219, 10.1586/eri.11.168 · DOI · Paper page
  48. Kalia, 2019, Quorum sensing inhibitors as antipathogens: biotechnological applications, Biotechnol Adv, 37, 68, 10.1016/j.biotechadv.2018.11.006 · DOI · Paper page
  49. Gökalsın, 2017, Reducing virulence and biofilm of Pseudomonas aeruginosa by potential quorum sensing inhibitor carotenoid: zeaxanthin, Microb Ecol, 74, 466, 10.1007/s00248-017-0949-3 · DOI
  50. Kitao, 2018, Molecular insights into function and competitive inhibition of Pseudomonas aeruginosa multiple virulence factor regulator, mBio, 9, 1, 10.1128/mBio.02158-17 · DOI
  51. Johansson, 2008, Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB, Chem Biol, 15, 1249, 10.1016/j.chembiol.2008.10.009 · DOI · Paper page
  52. Kadam, 2011, A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and Pseudomonas aeruginosa biofilms, Angew Chem Int Ed, 50, 10631, 10.1002/anie.201104342 · doi:10.1002/anie.201104342
  53. Cheng, 2021, Constructing nanostructured functional film on EH40 steel surface for anti-adhesion of Pseudomonas aeruginosa, Surf Coating Technol, 405, 1, 10.1016/j.surfcoat.2020.126683 · DOI
  54. Mittal, 2009, Urinary tract infections caused by Pseudomonas aeruginosa: a minireview, J Infect Publ Health, 2, 101, 10.1016/j.jiph.2009.08.003 · DOI · Paper page
  55. Diggle, 2020, Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat, Microbiology, 166, 30, 10.1099/mic.0.000860 · DOI · Paper page
  56. Chen, 2015, Composition, function, and regulation of T6SS in Pseudomonas aeruginosa, Microbiol Res, 172, 19, 10.1016/j.micres.2015.01.004 · DOI
  57. Sandri, 2018, Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice, Virulence, 9, 1008, 10.1080/21505594.2018.1489198 · DOI · Paper page
  58. Abbas, 2015, Inhibition of virulence factors of Pseudomonas aeruginosa by diclofenac sodium, Rom Arch Microbiol Immunol, 74, 79
  59. Sharma, 2021, Chemotherapeutic strategies for combating Staphylococcus aureus infections, Mini Rev Med Chem, 21, 1
  60. Waters, 2017, Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa, Thorax, 72, 666, 10.1136/thoraxjnl-2016-209265 · DOI · Paper page
  61. Torres-Barceló, 2014, A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages, PLoS One, 9, 1, 10.1371/journal.pone.0106628 · DOI · Paper page
  62. Pires, 2016, Genetically engineered phages: a review of advances over the last decade, Microbiol Mol Biol Rev, 80, 523, 10.1128/MMBR.00069-15 · DOI · Paper page
  63. Labrie, 2010, Bacteriophage resistance mechanisms, Nat Rev Microbiol, 8, 317, 10.1038/nrmicro2315 · DOI · Paper page
  64. Jeevanandam, 2018, Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations, Beilstein J Nanotechnol, 9, 1050, 10.3762/bjnano.9.98 · DOI · Paper page
  65. Döring, 2008, Vaccines and immunotherapy against Pseudomonas aeruginosa, Vaccine, 26, 1011, 10.1016/j.vaccine.2007.12.007 · doi:10.1016/j.vaccine.2007.12.007

Cited by

See all 66

Metadata

Authors
Jangra, V., Sharma, N., & Chhillar, A. K.
Venue
Microbes and Infection
Publisher
Elsevier BV
Published
2022-06
Volume
24
Issue
4
Pages
104950
ISSN
1286-4579
Cited by
66
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic approaches for combating Pseudomonas aeruginosa infections. https://app.cochat.ai/papers/10.1016/j.micinf.2022.104950
The paper
Jangra, V., Sharma, N., & Chhillar, A. K. (2022). Therapeutic approaches for combating Pseudomonas aeruginosa infections. Microbes and Infection. https://doi.org/10.1016/j.micinf.2022.104950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.